Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 165-172

  Bays, Harold E ^a   Brinton, Eliot A ^b   Triscari, Joseph ^c   Chen, Erluo ^c   MacCubbin, Darbie ^c   Maclean, Alexandra A ^c   Gibson, Kendra L ^c   Ruck, Rae Ann ^c   Johnson Levonas, Amy O ^c   O ’ Neill, Edward A ^c   Mitchel, Yale B ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Utah Foundation for Biomedical Research   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HDL; Hyperglycemia; LDL; Lipid modifying agents; Triglycerides

Indexed keywords

EZETIMIBE; FENOFIBRATE; FISH OIL; GEMFIBROZIL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; DELAYED RELEASE FORMULATION; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; INDOLE DERIVATIVE; MK-0524;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME;

AGED; BIOMARKERS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; MALE; MIDDLE AGED; NIACIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924540062     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S70907     Document Type: Article

References (25)

1. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004;27(Suppl 1):S68–S71.
2. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144:S33–S42.
3. Manzato E, Zambon A, Lapolla A, et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care. 1993;16: 469–475.
4. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59: 1153–1160.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143–3421.
6. Bays HE, Ballantyne C. What’s the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight fush? Curr Opin Lipidol. 2009;20:467–476.
7. Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfbrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfbrozil Study Group. Arch Intern Med. 2000;160:1177–1184.
8. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270–274.
9. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91: 1432–1436.
10. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004;62:229–234.
11. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586–1595.
12. Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin. 2008;24:1817–1821.
13. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodifed and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642–650.
14. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol. 2003;3:4.
15. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced fushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625–630.
16. Sturino C F, O’Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fuoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b] indol-3-Yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794–806.
17. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol. 1991; 40(Suppl 1):S49–S51.
18. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–1298.
19. Boden WE, Probstfeld JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
20. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: trial design, pre-specifed muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291.
21. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371: 203–212.
22. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570–2581.
23. MacLean A, McKenney JM, Scott R, et al. Effcacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol. 2011;18:37–45.
24. Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18(Suppl 1): 1–78.
25. Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013;62:1580–1584.